Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillinase-susceptible penicillin, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many beta-lactamase enzymes, extending its spectrum of activity to include many Gram-negative bacteria that produce these enzymes.
## Primary Indications
Piperacillin-tazobactam is indicated for the treatment of moderate to severe infections caused by piperacillin-susceptible organisms, including:
* Community-acquired pneumonia
* Nosocomial pneumonia
* Complicated intra-abdominal infections
* Complicated skin and skin-structure infections
* Complicated urinary tract infections (including pyelonephritis)
* Bacterial meningitis (in combination with an aminoglycoside if indicated)
* Febrile neutropenia (in combination with an aminoglycoside if indicated)
* Uncomplicated skin and skin-structure infections
## Adult Dosing
The usual adult dose is 3.375 grams every 6 hours or 4.5 grams every 6 or 8 hours administered by intravenous infusion over 30 minutes.
* **3.375 g (3 g piperacillin / 0.375 g tazobactam)**
* **4.5 g (4 g piperacillin / 0.5 g tazobactam)**
The choice of dose and frequency depends on the severity and type of infection. The maximum recommended daily dose is 18 grams (4.5 grams every 6 hours).
## Pediatric Dosing
Dosing in pediatric patients varies based on weight, age, and severity of infection. Dosing is typically calculated based on the piperacillin component.
* **Patients 2 months and older:** Recommended doses range from 80 mg to 112.5 mg of piperacillin component per kg of body weight every 6 or 8 hours, not to exceed the adult maximum dose of 4.5 grams per dose.
* Specific dosing recommendations for neonates and infants younger than 2 months are not established due to immature renal and hepatic function.
## Dose Adjustments
**Renal Impairment:**
* CrCl > 40 mL/min: No dose adjustment necessary.
* CrCl 20-40 mL/min: 2.25 g or 3.375 g every 6 hours.
* CrCl < 20 mL/min: 2.25 g every 6 hours or 3.375 g every 8 hours.
* For hemodialysis patients, administer a 2.25 g dose after each dialysis session.
**Hepatic Impairment:** No dose adjustment is recommended.
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillins, or beta-lactams.
* History of a severe allergic reaction (e.g., anaphylaxis) to a beta-lactam antibiotic.
## Adverse Effects
Common adverse effects include diarrhea, nausea, vomiting, rash, headache, insomnia, and injection site reactions.
Serious adverse effects include:
* Hypersensitivity reactions (anaphylaxis)
* Clostridioides difficile-associated diarrhea
* Seizures (especially with high doses or renal impairment)
* Hematologic abnormalities (e.g., neutropenia, thrombocytopenia)
* Hepatotoxicity
* Interstitial nephritis
## Key Drug Interactions
* **Aminoglycosides:** Concurrent use may lead to inactivation of the aminoglycoside; however, in certain serious infections (e.g., Pseudomonas aeruginosa infections), combination therapy may be beneficial. If combined, administer them separately.
* **Probenecid:** May increase and prolong piperacillin serum levels.
* **Neuromuscular blocking agents:** Piperacillin may prolong the action of vecuronium.
* **Warfarin:** Piperacillin may decrease the efficacy of warfarin. Monitor INR closely.
* **Methotrexate:** Piperacillin may decrease methotrexate levels. Monitor methotrexate levels.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for signs and symptoms of C. difficile-associated diarrhea.
* Monitor renal function, especially in patients with pre-existing renal impairment or those receiving nephrotoxic agents.
* Monitor complete blood count for hematologic abnormalities.
* Monitor liver function tests.
* For patients on warfarin, monitor INR.
* For patients on methotrexate, monitor methotrexate levels.
## Clinical Pearls
* The duration of therapy should be based on the severity and type of infection and the clinical response of the patient.
* Culture and sensitivity testing should be performed prior to treatment to identify the causative organism and its susceptibility to piperacillin-tazobactam.
* Reconstituted solutions should be used within the time specified by the manufacturer (typically 24 hours at room temperature or 48 hours refrigerated).
* Doses of 3.375 g and 4.5 g contain varying ratios of piperacillin to tazobactam. Ensure the correct formulation is used for the prescribed dose.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider to determine the appropriate treatment for any medical condition. Verify current prescribing information with the manufacturer's official product information before making any clinical decisions.*
